(Reuters) -Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage study that sets the stage for a new entrant to the obesity market next year.

People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of the popular medications, Zepbound. Eli Lilly, the maker of Zepbound, ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in ...

Higher 36 mg dose of orforglipron leads to 12.4% weight loss vs 0.9% for placebo Dropout rate due to side effects was about 10% for high-dose patients Lilly plans to file for approval of once-daily ...